M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
Launched by SPINAL KINETICS · Jul 23, 2021
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The M6®-C Artificial Cervical Disc study is looking at a new type of artificial disc, the M6-C™, to see how safe and effective it is for treating neck and arm pain caused by problems in the cervical spine, specifically at two connected levels between the C3 and C7 vertebrae. This study compares the M6-C™ disc to a traditional surgery called anterior cervical discectomy and fusion (ACDF). It is currently recruiting participants who are between 18 and 75 years old and have not found relief from their pain after at least six weeks of other treatments. Eligible participants will have specific symptoms like neck or arm pain, and their condition must be confirmed through tests like MRIs or X-rays.
If you join the study, you will receive either the new artificial disc or the standard surgery, and you will be monitored closely to see how well the treatment works for you. It’s important to know that there are certain medical conditions that would exclude someone from participating, such as having had previous neck surgeries, severe neck pain without other symptoms, or specific health issues that could complicate the surgery. This trial aims to improve treatment options for people with cervical disc problems, and your participation could help researchers learn more about this innovative approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of degenerative cervical radiculopathy with or without spinal cord compression requiring surgical treatment at two contiguous levels from C3 to C7 demonstrated by signs and/or symptoms of disc herniation and/or osteophyte formation (e.g. neck and/or arm pain, radiculopathy, etc.) and is confirmed by patient history and radiographic studies (e.g. MRI, CT, x-rays, etc.)
- • Inadequate response to conservative medical care over a period of at least 6 weeks or have the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management
- • Neck Disability Index score of ≥ 30% (raw score of ≥ 15/50)
- • Neck or arm pain Visual Analog Scale Score ≥ 4 on a scale of 0 to 10
- • Willing and able to comply with the requirements of the protocol including follow-up requirements
- • Willing and able to sign a study specific informed consent
- • Skeletally mature and at least 18 years old but not older than 75 years old
- Exclusion Criteria:
- • More than two cervical levels requiring surgery, or two non-contiguous levels requiring surgery
- • Previous anterior cervical spine surgery
- • Axial neck pain as the solitary symptom
- • Previous posterior cervical spine surgery (such as a posterior element decompression) that destabilizes the cervical spine
- • Advanced cervical anatomical deformity (such as ankylosing spondylitis, scoliosis) at either of the operative levels or adjacent levels
- • Symptomatic facet arthrosis
- • Less than four degrees of motion in flexion/extension at either of the index levels
- • Instability as evidenced by subluxation greater than 3 millimeters at either of the index or adjacent levels as indicated on flexion/extension x-rays.
- • Advanced degenerative changes (e.g., spondylosis) at either of the index vertebral levels as evidenced by bridging osteophytes, central disc height less than 4 millimeters and/or \< 50% of the adjacent normal intervertebral disc, or kyphotic deformity \> 11 degrees on neutral x-rays
- • Severe cervical myelopathy (i.e., Nurick's Classification greater than 2)
- • Active systemic infection or infection at the operative site
- • Co-morbid medical conditions of the spine or upper extremities that may affect the cervical spine neurological and/or pain assessment
- • Metabolic bone disease such as osteoporosis that contradicts spinal surgery
- • History of an osteoporotic fracture of the spine, hip or wrist
- • History of an endocrine or metabolic disorder (e.g. Paget's disease) known to affect bone and mineral metabolism
- • Taking medications that may interfere with bony/soft tissue healing including chronic steroid use
- • Known allergy to titanium, stainless steels, polyurethane, polyethylene, or ethylene oxide residuals
- • Fibromyalgia, Rheumatoid Arthritis (or other autoimmune disease), or a systemic disorder such as HIV or acute hepatitis B or C.
- • Insulin dependent diabetes
- • Medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion
- • Pregnant, or intend to become pregnant, during the course of the study
- • Severe obesity (Body Mass Index greater than 45)
- • Physical or mental condition (e.g. psychiatric disorder, senile dementia, Alzheimer's disease, alcohol or drug addiction) that would interfere with patient self-assessment of function, pain or quality of life.
- • Involved in current or pending spinal litigation where permanent disability benefits are being sought.
- • Incarcerated at time of study enrollment
- • Current participation in other investigational study.
About Spinal Kinetics
Spinal Kinetics is a pioneering medical device company focused on developing innovative solutions for spinal health and rehabilitation. With a commitment to advancing patient care, Spinal Kinetics specializes in the design and commercialization of cutting-edge spinal implants and technologies that enhance the quality of life for individuals suffering from back pain and related disorders. The company's rigorous clinical trials aim to validate the safety and efficacy of its products, ensuring they meet the highest standards of medical excellence. Driven by a team of experts in biomechanics and orthopedics, Spinal Kinetics is dedicated to transforming spinal treatment through research, collaboration, and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Salt Lake City, Utah, United States
Orange, California, United States
Long Beach, California, United States
Phoenix, Arizona, United States
St. Louis, Missouri, United States
Springfield, Massachusetts, United States
Saint Louis, Missouri, United States
Austin, Texas, United States
Santa Monica, California, United States
Southfield, Michigan, United States
East Syracuse, New York, United States
Austin, Texas, United States
Beverly Hills, California, United States
Orlando, Florida, United States
Urbana, Illinois, United States
Gainesville, Georgia, United States
Plano, Texas, United States
Englewood, New Jersey, United States
Aurora, Colorado, United States
Hartford, Connecticut, United States
Frisco, Texas, United States
Thousand Oaks, California, United States
Coeur D'alene, Idaho, United States
Vail, Colorado, United States
Cincinnati, Ohio, United States
Newport Beach, California, United States
Tampa, Florida, United States
Frisco, Texas, United States
Patients applied
Trial Officials
Frank Phillips, MD
Principal Investigator
Rush University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials